In Thursday's Blitz Daily, we take a look at technology powerhouse Apple ahead of its third-quarter earnings report following the closing bell. Thursday’s top options flow isn’t going to come as much of a shock... Because when Apple moves, it takes the entire Nasdaq with it — and everyone wants a piece!
Market makers have their implied move around $3.68 higher or lower for the tech titan’s earnings event — right in line with the move shares made by noon on Thursday!
It’ll be interesting to find out if what we see is what we get, or if the stock will continue to break toward new record highs.
But even if Apple is played out, I have four more unusual options bets ready and waiting — including two biotech names to improve the health of your portfolio.
P.S. If you weren’t able to make it to Tuesday’s live Emergency Trade Alert, reply directly to this email for details about this little-known biotech opportunity.
Aggressive “desk clearing” FDA approvals are fueling some of the easiest profits of 2021… And the next 61 days could be even bigger.
Researchers from Harvard and MIT noted in a recent report that “Approval spikes occur at the end of each calendar month,” and before the “end of the year in a kind of ‘desk-clearing’ activity.”
Disclaimer : The material in this document is for informational purposes based on our proprietary research. It is not an offering, specific recommendation, or a solicitation of an offer to buy or sell any securities mentioned or discussed herein.
Any performance results discussed herein represent past performance, are not a guarantee of future performance, and are not indicative of any specific investment.
Due to the timing of information presented, any investment performance reflected within this document may be adjusted after the publication and distribution of this material. There can be no assurance that the future performance of any specific investment, investment strategy, or product made reference to directly or indirectly in this communication will be profitable, be equal to any corresponding indicated historical performance levels or be suitable for your portfolio. Any investment results set forth in this document are not net of expenses and execution costs, nor do they account for other relevant trading or investment fees. Please visit wealthpress.com/terms for our full Terms and Conditions.
0 Response to "Did Market Makers Get It Right, or Does Apple Have Room to Run?"
Post a Comment